Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
About this study
To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
- Condition
- Acute Myeloid Leukemia
- Tested
- Chidamide, Venetoclax, azacitidine, Anthracyclines or anthraquinones, cytarabine
- Sponsor
- Guangdong Provincial People's Hospital
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Acute Myeloid Leukemia
- Diagnosed with AML (the diagnostic criteria refer to WHO2022 standard, non-APL), and have not received systemic anti-leukemia therapy (except hydroxyurea, low-dose cytarabine and other tumor reduction pretreatments);
- Age ≥18 years old;
- ECOG≤4;
- The fertile woman agrees to use effective contraception during the treatment period and up to 3 months after the end of the treatment; Sign the informed consent form.
Exclusion 6
- Known history of allergy to the investigational drug;
- Resistance to azacytidine, azacitidine, Venetoclax;
- Inability to take oral medication;
- Combined with uncontrolled active infections (including bacterial, fungal or viral infections);
- Combined with uncontrolled major organ dysfunction: cardiac insufficiency, decompensated liver insufficiency, moderate/severe renal insufficiency, etc.;
- Participating in other clinical studies that affect the main purpose of this study; Patients deemed unsuitable for participation in this study.
Where
13 sites, 13 recruiting
Dongguan General Hosptial
Dongguan, Guangdong, China
Foshan First People's Hospital
Foshan, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China
and 7 more sites on ClinicalTrials.gov
Contact
-
Jianyu Weng
020-83827812 wengjianyu@gdph.org.cn
-
Du Xin
020-83827812 xind@gdph.org.cn
Potential match only. Final eligibility is determined by the study team.